Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;101(7):794-802.
doi: 10.3324/haematol.2015.132761.

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

Santosha Vardhana  1 , Anas Younes  2
Affiliations
Review

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

Santosha Vardhana et al. Haematologica. 2016 Jul.

Abstract

Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a dense immune microenvironment. However, the role of the immune microenvironment, particularly T and B cells, in either promoting or restricting Classical Hodgkin lymphoma growth remains undefined. Recent dramatic clinical responses seen using monoclonal antibodies against PD-1, a cell surface receptor whose primary function is to restrict T cell activation, have reignited questions regarding the function of the adaptive immune system in classical Hodgkin lymphoma. This review summarizes what is known regarding T cells, B cells, and immune checkpoints in classical Hodgkin lymphoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Suppression of anti-tumor T cell responses by the CHL microenvironment. (A) RS cells and stromal cells secrete cytokines, chemokines, and other soluble immunomodulatory factors, such as IL-10, CCL17/TARC, galectin-1, and indoleamine 2,3-dioxygenase (IDO) which both recruit Th2 and regulatory CD4+ T cells and favor the differentiation of tumor-infiltrating T cells into regulatory and Th2 cells via the induction of lineage specific transcription factors Gata3 (Th2) and FoxP3 (Treg). (B) RS cells evade recognition by CD8+ and CD4+ T cells by downregulating expression of MHC-I and MHC-II in the majority of cases. They also express ligands that activate negative regulatory receptors present on T cells, such as PD-1. Conversely, RS cells are able to derive growth signals from CD40L, which is present on the majority of T cells within the microenvironment and activates CD40 on RS cells, driving NF-κB signaling and RS cell proliferation.
Figure 2.
Figure 2.
A model for anti-tumor immunity in the setting of checkpoint blockade. (A) In solid tumors, anti-tumor immunity is mediated primarily by CD8+ T cell responses that are amplified in the setting of PD-1 blockade. However, in CHL this is mitigated by downregulation of MHC-I in the majority of cases. (B) This may predispose RS cells to killing by NK cells, which also express PD-1. Similarly, RS cell downregulation of MHC-II may limit CD4+ T cell responses following checkpoint blockade, but CD4+ T cells can also be primed by other APCs within the CHL microenvironment that do express MHC-II. Additionally, checkpoint blockade may impair the immunosuppressive function of infiltrating regulatory T cells, increasing productive T cell activation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hodgkin. On some Morbid Appearances of the Absorbent Glands and Spleen. Med Chir Trans. 1832;17:68–114. - PMC - PubMed
    1. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184(4):1495–1505. - PMC - PubMed
    1. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA. 1994;91(23):10962–10966. - PMC - PubMed
    1. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. - PMC - PubMed
    1. Moskowitz CH, Ribrag V, Michot JM, et al. PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). Blood. 2014;124(21):290 abstr.

MeSH terms